Results 181 to 190 of about 34,211 (250)

Variability in anthracycline dose conversions and cardiotoxicity monitoring: insights from hospital pharmacists on institutional protocols in oncology practice. [PDF]

Support Care Cancer
Ditta SA, Jongbloed F, Manintveld OC, Brugma JD, Wlazlo N, Bos MEMM, van der Kuy HM, Mathijssen RHJ.   +7 more
europepmc   +1 more source

Use of Metronomic Chemotherapy in Hormone Receptor‐Positive/HER2‐Negative Metastatic Breast Cancer: A Retrospective Multicenter Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Purpose The optimal chemotherapy strategy after progression on cyclin‐dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor‐positive/human epidermal growth factor receptor 2‐negative (HR+/HER2−) metastatic breast cancer remains a matter of controversy.
Lara Laini, Deborah Cosentini, Marta Laganà, Salvatore Grisanti, Giulia Scartabellati, Gianluca Fogazzi, Salvatore Strazzeri, Vito Amoroso, Greta Schivardi, Rebecca Pedersini, Alfredo Berruti, Antonella Turla   +11 more
wiley   +1 more source

Anthracycline-induced left atrioventricular dyssynchrony in children with leukemia: a cardiac magnetic resonance imaging study of functional and strain analysis. [PDF]

Front Cardiovasc Med
Liao Y, Jia Y, Yang Z, Xie L, Xiong S, Wang Y, Lei X, Guo Y, Xu R.   +8 more
europepmc   +1 more source

Optimizing the ER Cutoff in HER2‐Positive Breast Cancer: ER ≥ 50% Predicts Low pCR Rates and Resistance to Antibody‐Drug Conjugates in the Neoadjuvant Setting

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Estrogen receptor (ER)‐positive/HER2‐positive breast cancer demonstrates significantly lower rates of pathological complete response (pCR) to neoadjuvant HER2‐targeted therapies compared to ER‐negative/HER2‐positive disease. However, the optimal ER positivity cutoff for clinically meaningful patient stratification remains undefined.
Tian Du, Min Lin, Gehao Liang, Yan Wang, Hao Wu, Zixuan Zhao, Luhao Sun, Jun Tang   +7 more
wiley   +1 more source

Cardiometabolic Risk and Awareness of Anthracycline-Related Cardiotoxicity in Survivors of Childhood Cancer: A Population-Based Study. [PDF]

J Pediatr Hematol Oncol
Viggósdóttir VH, Helgason H, Jónsdóttir H, Aspelund T, Bjarnason R, Jarfelt M.   +5 more
europepmc   +1 more source

Low‐Dose Cytarabine Plus G‐CSF Induction in Pediatric M2 Acute Myeloid Leukemia: A Multicenter Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT This retrospective secondary analysis of the multicenter randomized CALS III‐AML18 trial evaluated the efficacy and safety of low‐dose chemotherapy (LDC) compared with standard‐dose chemotherapy (SDC) in children with M2 acute myeloid leukemia (AML‐M2). A total of 221 children were included, with 109 in the LDC arm and 112 in the SDC arm.
Wenxin Ou, Xiaohua Zhu, Jun Lu, Hongsheng Wang, Ning Liao, Yufeng Liu, Hua Jiang, Qi An, Xiaojun Yuan, Hailong He, Ningling Wang, Jixia Luo, Xiuli Ju, Qian‐Fei Wang, Minghua Yang, Cheng Cheng, Peifang Xiao, Liangchun Yang, Li Gao, Raul C. Ribeiro, Shaoyan Hu, Xiaowen Zhai   +21 more
wiley   +1 more source

Safety and Treatment Efficacy of Systemic, Locoregional, and Nanoparticle Encapsulated Anthracycline Chemotherapy: Insights Into Cardiotoxicity. [PDF]

Arterioscler Thromb Vasc Biol
Hammond ST, Brandt L, Kong AL, White SB, Lewandowski D, Beyer AM.   +5 more
europepmc   +1 more source

Actinomycin Analogs From Streptomyces polyantibioticus S4D258: Structural Elucidation and Antiproliferative Activity Against Triple‐Negative Breast Cancer

Chemistry &Biodiversity, Volume 23, Issue 10, October 2026.
Fifteen new actinomycin analogs, named actinomycins H1–H15, are identified from S. polyantibioticus S4D258. Actinomycins H7–H15 are truncated actinomycin analogs. Actinomycins H1–H6 and H9 exhibit significant antiproliferative activities against both MDA‐MB‐231 and 4T1 TNBC cells.
He Pang, Xiao‐Min Huang, Usama Ramadan Abdelmohsen, Li Shen, Jun Wu   +4 more
wiley   +1 more source

Cholesterol Metabolism in Cancer Patients: Mechanisms, Treatment-Related Effects, and Cardio-Oncology Management. [PDF]

Oncol Res
Piscione M, Pala B, Cribari F, Gualtieri P, Gaudio D, Perrone MA, Di Renzo L.   +6 more
europepmc   +1 more source